Pyridostigmine reduces mortality of patients with severe SARS-CoV-2 infection: A phase 2/3 randomized controlled trial

• Main Authors: Sergio Fragoso-Saavedra (Author), Isaac Núñez (Author), Belem M. Audelo-Cruz (Author), Sarahi Arias-Martínez (Author), Daniel Manzur-Sandoval (Author), Alejandro Quintero-Villegas (Author), H. Benjamín García-González (Author), Sergio L. Carbajal-Morelos (Author), Sergio PoncedeLeón-Rosales (Author), José Gotés-Palazuelos (Author), José A. Maza-Larrea (Author), J. Javier Rosales-de la Rosa (Author), Dafne Diaz-Rivera (Author), Edgar Luna-García (Author), Elvira Piten-Isidro (Author), Perla M. Del Río-Estrada (Author), Mario Fragoso-Saavedra (Author), Yanink Caro-Vega (Author), Isabella Batina (Author), León Islas-Weinstein (Author), David A. Iruegas-Nunez (Author), Juan J. Calva (Author), Pablo F. Belaunzarán-Zamudio (Author), Juan Sierra-Madero (Author), José C. Crispín (Author), Sergio Iván Valdés-Ferrer (Author)
• Format: Book
• Published: BMC, 2022-11-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Abstract: Background: Respiratory failure in severe coronavirus disease 2019 (COVID-19) is associated with a severe inflammatory response. Acetylcholine (ACh) reduces systemic inflammation in experimental bacterial and viral infections. Pyridostigmine increases the half-life of endogenous ACh, poten...